Fig. 6.
Activity of MX-2401 in a bronchoalveolar pneumonia model (S. pneumoniae ATCC 6303). Total doses of MX-2401 are shown (the drug was administered at 1 and 4 h postinfection). Log10 CFU/ml reductions versus control group are shown in parentheses.